Considerations and quality controls when analyzing cell-free tumor DNA

Circulating cell-free tumor DNA (ctDNA) is a promising biomarker in cancer. Ultrasensitive technologies enable detection of low (< 0.1%) mutant allele frequencies, a pre-requisite to fully utilize the potential of ctDNA in cancer diagnostics. In addition, the entire liquid biopsy workflow needs t...

Descripción completa

Detalles Bibliográficos
Autores principales: Johansson, Gustav, Andersson, Daniel, Filges, Stefan, Li, Junrui, Muth, Andreas, Godfrey, Tony E., Ståhlberg, Anders
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Special Issue on Liquid Biopsy & Biomarkers, Edited by Dr Michael Pfaffl
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416156/
https://www.ncbi.nlm.nih.gov/pubmed/30906693
http://dx.doi.org/10.1016/j.bdq.2018.12.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416156/
https://www.ncbi.nlm.nih.gov/pubmed/30906693
http://dx.doi.org/10.1016/j.bdq.2018.12.003

Ejemplares similares